Outcomes of hepatitis B immunoglobulin and hepatitis B vaccination in high-risk newborns born to HBeAg-positive mothers

Biomed J. 2022 Oct;45(5):798-805. doi: 10.1016/j.bj.2021.11.007. Epub 2021 Nov 19.

Abstract

Background: To evaluate the protective efficacy of a hepatitis B (HB) vaccination program in Taiwan among high-risk children.

Methods: Children born to HBeAg-positive mothers from 2001 to 2010 were invited back. Blood samples for hepatitis B virus (HBV) seromarkers were taken and the children underwent hepatobiliary ultrasonography. Perinatal factors including delivery mode and vaccination history were collected from their medical records. According to the results of HBV serological markers, the children were initially classified into five groups: HBV naïve, HB vaccine responder, HBsAg carrier, recovered from HBV infection, and anti-HBc-positive alone. Children in the HBV naïve and anti-HBc-positive alone groups who presented with an anamnestic response after a booster HB vaccine were re-assigned to the vaccine responder and recovered from infection groups, respectively.

Results: All of the 196 enrolled children received postnatal hepatitis B immunoglobulin (HBIG) and HB vaccinations, of whom one was HBV naïve (0.5%), 109 were vaccine responders (55.6%), 21 were carriers (10.7%), and 65 recovered from infection (33.2%). Among the 21 carriers, 14 (66.7%) presented in the immunotolerant phase. Cesarean section was the only significant perinatal factor between the carriers (5.3%) and those who recovered from infection (37.7%) (p = 0.007).

Conclusion: In this study, there was a 43.9% HBV infection rate and 10.7% HBsAg carrier rate in high-risk Taiwanese children even after receiving HBIG and HB vaccinations. C-section may protect newborns from becoming HBsAg carriers, while HBV genotype and time of HBIG injection did not contribute to the HBV carrier rate.

Keywords: Hepatitis B Antibodies; Hepatitis B e Antigens; Mass vaccination.

MeSH terms

  • Cesarean Section
  • Child
  • Female
  • Hepatitis B Surface Antigens*
  • Hepatitis B Vaccines / therapeutic use
  • Hepatitis B e Antigens
  • Hepatitis B virus / genetics
  • Hepatitis B* / prevention & control
  • Humans
  • Immunoglobulins / therapeutic use
  • Infant, Newborn
  • Pregnancy
  • Vaccination

Substances

  • Hepatitis B Surface Antigens
  • hepatitis B hyperimmune globulin
  • Hepatitis B e Antigens
  • Hepatitis B Vaccines
  • Immunoglobulins